Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by stockbuphoonon Aug 18, 2021 10:05am
51 Views
Post# 33722835

PRV - why is Thomson not doing bridge loan?

PRV - why is Thomson not doing bridge loan?Pritchard in response to Yasmin of Piper Liminal- In terms of the closing of the PRV, as we've mentioned this is subject to certain closing conditions. They're predominantly driven by the US antitrust clearance review. Yasmeen, as you probably know, there is a standard time line for that. We don't have control over that time line. But there's a standard process to go through that's fairly well documented. So we would anticipate that all being well with that, that we would receive the funds certainly this year, and hopefully before the time that we have the next analyst call for our Q3 results.
<< Previous
Bullboard Posts
Next >>